FILSPARI's dual-indication launch drives 71% revenue growth, but scaling into FSGS and defending against emerging IgAN entrants is the proof point

Bull

FSGS patient identification and physician adoption accelerate as Travere's rare kidney disease commercial infrastructure—already built for IgAN—efficiently reaches the smaller, underserved FSGS population. Five-year DUPLEX open-label extension durability data reinforce physician confidence in long-term use, supporting formulary positioning and reducing switching risk. If H2 2026 revenue maintains a sequential growth trend, Travere could approach profitability on the strength of FILSPARI alone, validating the commercial strategy.

Bear

FSGS represents a structurally smaller addressable population than IgAN, and the rapid Q2 growth rate may reflect launch stocking and early adopters rather than sustainable underlying demand, setting up a deceleration that disappoints consensus expectations. Competition from pipeline assets targeting IgAN—including Climb Bio's budoprutug (C5a receptor antagonist), Biohaven's BHV-1400, and Jade Biosciences' JADE-001—could erode FILSPARI's IgAN share before FSGS volumes fully offset any pressure. Payer pushback or prior authorization burdens in FSGS, a less precedented reimbursement environment than IgAN, could limit net price realization.